European Commission has approved Cosentyx (secukinumab) for Rx of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) based on results of the Phase III PREVENT trial. (NOT yet FDA/US approved for nr-axSpA) https://t.co/DAWWoG6MJP